Drugs / rAAV2tYF-GRK1-RPGR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03316560 | Apr 2018 → Nov 2023 | retinitis pigmentosa | Beacon Therapeutics | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2tYF-GRK1-RPGR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03316560 ↗ |
| Known as | AGTC-501 | “A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center...” NCT03316560 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR)” NCT03316560 ↗ |
| Route | Other | “by subretinal injection in one eye” NCT03316560 ↗ |
| Target | RPGR | “Adeno-associated virus vector expressing a human RPGR gene” NCT03316560 ↗ |